Post by BioVendor Group

Meet the future of diabetes diagnostics In the latest issue of the Discover BioVendor Group newsletter, we introduce a comprehensive diabetes panel that combines both functional and autoimmune markers within a single, fully automated CLIA workflow. This innovative solution delivers a significant market advantage by offering GAD65 and IA-2 markers in a CLIA format, enabling earlier and more accurate differentiation between Type 1, Type 2, and LADA diabetes. By replacing traditional ELISA and RIA methods, the platform improves laboratory efficiency and safety through: – Faster processing – Higher throughput – Elimination of radioactive materials Discover how CLIA-based diabetes differentiation can transform your laboratory workflow and support more precise diagnostics. #CLIA #diabetes #autoimmunity #biotechnology #diagnostics #BioVendor